bioMérieux – Information financière du 3ème trimestre 2026
Filed with Euronext · · 9 pages · French
Earlier from bioMerieux
- Octobre 2026 - Déclaration sur le nombre d\'actions composant le capital social et sur le nombre de droits de vote correspondant
- bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
- WHO Grants Emergency Use Listing for BIOFIRE Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
- bioMerieux: BioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
- bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
Later from bioMerieux
All bioMerieux news releasesFollow bioMerieux into a list and get an email when it puts out news.
Follow bioMerieux